Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Study of Endocrine-Related Conditions and Physiology

for
Endocrine Disease
Location: Bethesda MD
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Sex: All

Age: 18 - 70+

Code: NCT03867448

Recruiting

A Study of Music Therapy for Anxiety in People With Cancer

for
Cancer
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07845422

Recruiting

Preserving Physical Function in Older Adults With Cancer: Impact of an Optimizing Nutrition Intervention Applied Before and After Surgery

for
Cancer
Location: Durham NC
Sponsor: VA Office of Research and Development

Sex: All

Age: 55+

Code: NCT05912257

Recruiting

myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports

for
Cancer, Relapsed Cancer, Refractory Cancer
Location: Sioux Falls SD
Sponsor: Cellworks Group Inc.

Sex: All

Age: 0+

Code: NCT05693831

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for
Solid Tumors, Hematologic Malignancies
Location: Quebec, Sherbrooke, White Plains NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT03486873

Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

for
Refractory Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 1 - 25

Code: NCT06006273

Phase 1, Recruiting

Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain

for
Cancer, Breakthrough Cancer Pain
Location: Berlin NJ
Sponsor: Tetra Bio-Pharma

Sex: All

Age: 18+

Code: NCT03564548

Phase 2, Recruiting

AMT-116 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Dallas TX
Sponsor: Multitude Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT05725291

Phase 1, Recruiting

EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer

for
Cancer, Breast Cancer
Location: Pittsburgh PA
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Sex: Female

Age: 20 - 70+

Code: NCT07704476

Recruiting

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

for
Locally Advanced Solid Tumor
Location: East Brunswick NJ, Dallas TX, Los Angeles CA
Sponsor: Fortvita Biologics (USA)Inc.

Sex: All

Age: 18+

Code: NCT06349408

Phase 1, Recruiting

SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer Care

for
Cancer, Financial Toxicity
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18+

Code: NCT07410689

Recruiting

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

for
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
Location: Boston MA, Fairfax VA, Canton OH, Detroit MI,
Sponsor: Chipscreen Biosciences, Ltd.

Sex: All

Age: 18+

Code: NCT05271292

Phase 1, Phase 2, Recruiting

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

for
Tumor Hyperinsulinism (Tumor HI)
Location: Boston MA, New York NY, Bethesda MD, Canton OH,
Sponsor: Rezolute

Sex: All

Age: 18+

Code: NCT06881992

Phase 3, Recruiting

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

for
Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC,
Location: New York NY, Fairfax VA
Sponsor: ORIC Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06816992

Phase 1, Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

for
Advanced Solid Malignancies
Location: Boston MA, New York NY, Chicago IL, Houston TX,
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT05417594

Phase 1, Phase 2, Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

for
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer,
Location: New Brunswick NJ
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT02628067

Phase 2, Recruiting

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

for
Hematopoietic and Lymphatic System Neoplasm,
Location: New York NY, Augusta GA, Grand Rapids MI, Chicago IL,
Sponsor: National Cancer Institute LAO

Sex: All

Age: 0+

Code: NCT02474160

Recruiting

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

for
Primary Central Nervous System Lymphoma, Recurrent Cancer,
Location: Boston MA, New York NY
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04421560

Phase 1, Phase 2, Recruiting

A ProspectiveTrial Using Video Images in Advance Care Planning in Hospitalized Seriously Ill Patients With Advanced Cancer

for
Advanced Cancer
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 21+

Code: NCT01527331

Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

for
Solid Tumor, Adult
Location: Washington D.C. DC, Florida City FL, Huntersville NC,
Sponsor: DualityBio Inc.

Sex: All

Age: 18+

Code: NCT06554795

Phase 1, Phase 2, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial